"Replace Frontline Treatment for all Type II Diabetics"

[piccolopete]

" Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients." ....Al Mann

This was the rationale I believe Al used to declare that Afrezza could be the most important new drug release, ever. Unfortunately, the Phase 3 trial results just released did not validify this observation and bullishness.

[notamnkdmillionaire]

Sept 12, 2013 16:46:26 GMT -5 piccolopete said:

" Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients." ....Al Mann

This was the rationale I believe Al used to declare that Afrezza could be the most important new drug release, ever. Unfortunately, the Phase 3 trial results just released did not validify this observation and bullishness.

Guess what? The trial was closely controlled as all trials are. The beauty of doctor/patient interaction is one where they can experiment to get the desired results. AGain, the trials hit the end points that MNKD needed to hit per the FDA. Nit picking like you are is fine but doesn't change the fact that MNKD, again, hit a bullseye in regards to what the FDA wanted. 

I would suggest you sell your shares, assuming you DO have shares, as you truly don't are nit picking at negatives instead of seeing the bigger picture, that again, MNKD delivered in what the FDA wanted when it issued it's previous CRL.